Management to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GL

Palisade Bio offers a speculative early-stage opportunity, advancing PALI-2108, a gut-restricted PDE

ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative coli

ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative coli

Board strengthened with extensive biotechnology leadership, strategic transactions and capital marke

Presentation to highlight fibrostenotic Crohn's disease biology and the potential of a locally b

Presentation to highlight fibrostenotic Crohn's disease biology and the potential of a locally bioac

Management presentation to take place on Thursday, June 4 th at 3:45 PM ET Register for the webcast

Stock futures rise on Wednesday, with Verra Mobility's shares plunging 45% after Avis Budget Gro

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which missed the analyst c

Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for tr

Data demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure

Data demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure

Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDTDenver, CO, April 16, 2026 (GLOBE

Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDT Denver, CO, April 16, 2026 (GLOBE

Shares of Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) have received a consensus rating of "M

Wolfe Research analyst Andy Chen initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperfo

Virtual presentation scheduled for Thursday, April 16th at 2:15 PM ET Access the webcast here Denver

PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two we

PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two we

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Palisade Bio (NASDAQ:PAL

I initiate Palisade Bio with a speculative buy, citing its differentiated microbiome-activated PDE4

Shares of Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) have earned an average rating of "Mode

Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or th

Stifel analyst Alex Thompson initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating a

Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of infl

Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of infl

Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) was the recipient of a large growth in short int

Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrost

Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a clinical-stage bi

B. Riley Securities analyst William Woods initiates coverage on Palisade Bio (NASDAQ:PALI) with a

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the

Clear Street analyst Kaveri Pohlman initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy r

PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Palisade Bio (NASDAQ:PALI) with a Over

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.38) per share which missed the analyst c

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibro

Steven Cohen's Point72 Asset Management has doubled the S&P 500's three-year return and